Researchers have developed a groundbreaking gene therapy that may prevent and even reverse the accumulation of amyloid plaques in the brain, a key factor in Alzheimer’s disease. This new treatment, known as AM805, uses a lysosomal enzyme to target amyloid buildup inside and outside neurons. Unlike current monoclonal antibody drugs that only slow cognitive decline, this one-time gene therapy aims to restore neuronal function and could significantly change how Alzheimer’s is treated.

For people concerned about aging and cognitive health, this therapy offers hope. The research indicates that AM805 can reduce amyloid levels by 60-80% in animal models, which correlates with functional improvements in brain health. This is particularly relevant for those who want to maintain their memory and cognitive abilities as they age. If successful in humans, this therapy could provide a more effective option for preventing or reversing Alzheimer’s symptoms.

The evidence for AM805 comes from preclinical studies in mouse models of Alzheimer’s disease, showing promising results in reducing amyloid levels. While this is an early-stage development, researchers plan to move forward with clinical trials and seek regulatory approval in the U.S. and U.K. by 2027. The findings presented at the 2026 American Society of Gene & Cell Therapy meeting highlight the potential of this therapy, but it’s important to note that it has not yet been tested in humans.

As this research progresses, staying informed about new treatments and participating in clinical trials may be beneficial for those at risk of Alzheimer’s. Keeping a healthy lifestyle, including a balanced diet and regular exercise, can also support brain health while we await more concrete treatment options.

Source: globenewswire.com